Submitted by Anonymous (not verified) on 7 February 2025 - 15:59
Human medicines European public assessment report (EPAR): Kesimpta, ofatumumab, Date of authorisation: 26/03/2021, Revision: 12, Status: Authorised
Source:
Human medicines European public assessment report (EPAR): Kesimpta, ofatumumab, Date of authorisation: 26/03/2021, Revision: 12, Status: Authorised